Table 2. Characteristics of included studies patients.
| Author /year | Connolly/2009 | Patel/2011 | Granger/2013 | Hori/2012 | Lau/2017 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Dabigatran 110 mg | Dabigatran 150 mg | Warfarin | Rivaroxaban | Warfarin | Apixaban | Warfarin | Rivaroxaban | Warfarin | Dabigatran | Warfarin |
| Number | 6,015 | 6,076 | 6,022 | 7,131 | 7,133 | 9,120 | 9,081 | 639 | 639 | 3,268 | 4,884 |
| Age-years ± SD | 71.4 ± 8.6 | 71.5 ± 8.8 | 71.6 ± 8.6 | 73 | 73 | 70 | 70 | 71.0 | 71.2 | 74.2 ± 10.1 | 73.3 ± 11.0 |
| Male (%) | 3,868(64.3) | 3,840(63.2) | 3,812(63.3) | 4,300(60.3) | 4,301(60.3) | 5,882(64.5) | 5,903(65) | 530(82.9) | 500(78.2) | 1,611(49.3) | 2,489(51) |
| CHA2DS2/CHA2DS2-VASc score | 2.1 ± 1.1 | 2.2 ± 1.2 | 2.1 ± 1.1 | 3.48 ± 0.94 | 3.46 ± 0.95 | 2.1 ± 1.1 | 2.1 ± 1.1 | 3.27 | 3.22 | 2.1 ± 1.5 | 2.1 ± 1.6 |
| TIA/Stroke history (%) | 1,197(19.9) | 1,233(20.3) | 1,192(19.8) | 3,915(54.9) | 3,895(54.6) | 1,751(19.2) | 1,789(19.7) | 408(63.8) | 405(63.4) | 1,094(33.5) | 1,515(31.0) |
| Heart failure (%) | 1,937(32.2) | 1,932(31.8) | 1,921(31.9) | 4,464(62.6) | 4,444(62.3) | 3,238(35.5) | 3,215(35.4) | 264(41.3) | 257(40.2) | 690(21.1) | 1,270(26.0) |
| Myocardial infarction (%) | 1,011(16.8) | 1,027(16.9) | 970(16.1) | 1,184(16.6) | 1,284(18.0) | 1,322(14.5) | 1,262(13.9) | 45(7.0) | 53(8.3) | NA | NA |
| Diabetes (%) | 1,408(23.4) | 1,404(23.1) | 1,409(23.4) | 2,881(40.4) | 2,818(39.5) | 2,280(25.0) | 2,261(24.9) | 249(39.0) | 237(37.1) | 984(30.1) | 1,402(28.7) |
| prior fractures (%) | NA | NA | NA | NA | NA | NA | NA | NA | NA | 234(7.2) | 336(6.9) |
| Osteoporosis (%) | NA | NA | NA | NA | NA | NA | NA | NA | NA | 38(1.2) | 53(1.1) |
| COPD (%) | NA | NA | NA | 756(10.6) | 742(10.4) | NA | NA | NA | NA | 270(8.3) | 406(8.3) |
| CKD (%) | NA | NA | NA | NA | NA | NA | NA | NA | NA | 94(2.9) | 181(3.7) |
| Aspirin (%) | 2,406(40.0) | 2,351(38.7) | 40.6 | 2,589(36.3) | 2,618(36.7) | 2,855(31.3) | 2,770(30.5) | NA | NA | NA | NA |